BTG revises annual revenue forecast higher

Healthcare company BTG said on Thursday it has delivered robust full-year results driven by sales across its speciality pharmaceuticals and licensing and biotechnology divisions.

Healthcare company BTG said on Thursday it has delivered robust full-year results driven by sales across its speciality pharmaceuticals and licensing and biotechnology divisions.

The group expects revenue of £230m for the year ended March 31st 2013, according to a trading update ahead of the annual financial statement.

Royalties from products including prostate cancer treatment Zytiga have helped boost results since January when revenue was pegged between £205m to £215m.

Results were also bolstered by favourable exchange rate movements and an agreement of a final sum relating to the discontinued CytoFab programme for treatment of severe sepsis.

Second stage trials of CytoFab - an experimental medicine owned by BTG but licensed to AstraZeneca - were ceased last August after the drug failed significantly to aid patients.

On the flip side, the company successfully completed the US phase two trial programme for Varisolve and submission of a new drug application seeking approval of PEM as a comprehensive treatment to improve the symptoms and appearance of varicose veins.

BTG also in the US launched Voraxaze (glucarpidase), a treatment for life-threatening toxicity in patients with renal impairment who are receiving high-dose methotrexate therapy.

Progress was made towards the submission of humanitarian device exemption applications in the US for the novel pre-loaded Precision Bead and Paragon Bead for use in uveal melanoma liver metastases and intrahepatic cholangiocarcinoma respectively.

"There has been good progress across the business," Chief Executive Louise Makin said.

"Our specialty pharmaceuticals and licensing and biotechnology businesses continue to give us a strong financial underpin. We have a clear strategy to create further value from the cash we are generating, by conducting studies to expand the uses of our interventional oncology products and through the acquisition of complementary products."

RD

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Four investment trusts for income investors to buy now
Investment trusts

Four investment trusts for income investors to buy now

Some high-yielding listed lending funds have come through the crisis with flying colours. David Stevenson picks four of the best.
12 Apr 2021
Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021